Royce & Associates LP increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 57.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,601,523 shares of the biopharmaceutical company’s stock after buying an additional 1,308,035 shares during the quarter. Royce & Associates LP’s holdings in Esperion Therapeutics were worth $13,326,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in shares of Esperion Therapeutics by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 945,491 shares of the biopharmaceutical company’s stock worth $2,506,000 after acquiring an additional 384,095 shares during the last quarter. AIGH Capital Management LLC increased its holdings in Esperion Therapeutics by 33.3% during the 4th quarter. AIGH Capital Management LLC now owns 4,000,000 shares of the biopharmaceutical company’s stock worth $14,800,000 after purchasing an additional 1,000,000 shares during the period. Integral Health Asset Management LLC purchased a new position in Esperion Therapeutics during the 3rd quarter worth $3,975,000. Vanguard Group Inc. increased its holdings in Esperion Therapeutics by 23.6% during the 4th quarter. Vanguard Group Inc. now owns 14,945,454 shares of the biopharmaceutical company’s stock worth $55,298,000 after purchasing an additional 2,853,005 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Esperion Therapeutics during the 3rd quarter worth $476,000. 47.39% of the stock is owned by institutional investors.
Esperion Therapeutics Price Performance
Shares of NASDAQ ESPR opened at $3.13 on Thursday. The stock has a market capitalization of $805.76 million, a P/E ratio of -52.17, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91. Esperion Therapeutics, Inc. has a 1-year low of $0.79 and a 1-year high of $4.18. The business has a fifty day moving average price of $2.60 and a 200 day moving average price of $3.12.
Analyst Ratings Changes
ESPR has been the topic of several research reports. Needham & Company LLC downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Citizens Jmp downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Cantor Fitzgerald downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Finally, HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective on the stock. in a report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $5.54.
View Our Latest Stock Analysis on ESPR
Esperion Therapeutics Profile
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
Read More
- Five stocks we like better than Esperion Therapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
